Objectives: In pancreatic cancer (PaC), the prevalence of diabetes mellitus (DM), especially new-onset DM (e36 months of PaC diagnosis), is high. To determine if this observation is unique to PaC, we compared the prevalence and characteristics of DM in lung, breast, prostate, and colorectal cancers with PaC and noncancer controls.
BACKGROUND
Diabetes mellitus (DM) is a group of heterogeneous disorders that is characterized by hyperglycemia. In 2010, 10.9 million or 26.9% US residents 65 years or older carried a diagnosis of DM. 1 The burden of DM is increasing worldwide and is associated with acute and chronic complications, leading to significant morbidity and mortality. 2 Similar to DM, the prevalence of cancer has also been increasing worldwide. According to the National Cancer Institute, there were an estimated 11.7 million cases of cancer in the United States in 2007. 3 The association between DM and cancer has long been debated. 4 Epidemiologic studies have demonstrated an increased risk (relative risk, 1.18Y2.51) of certain cancers (breast, colorectal, pancreatic, liver, endometrial, and bladder) in patients with DM. 5 The relevance of this finding is complicated by the fact that both DM and cancer have similar risk factors (eg, age, obesity, family history, and others), which might confound the results of these studies. 4, 5 Hyperinsulinemia also likely favors the development of cancer in patients with DM because insulin is a growth factor with not only metabolic but also mitogenic effects. 5 Further, some medications used in the treatment of DM have been postulated to stimulate insulin-mediated mitogenesis leading to a heightened risk of cancer in treated patients. 4Y6 More specifically, long-standing DM (onset 936 months before the diagnosis of pancreatic cancer [PaC]) is considered a risk factor (relative risk, 1.73Y1.94) for the development of PaC. 5, 7 In addition, abnormalities of glucose metabolism become increasingly evident in the time period leading to the diagnosis of PaC. 8 In our own studies, we have shown that approximately 85% of patients with PaC have an abnormal fasting glucose and nearly half have DM, which is frequently new onset, that is, it develops in the 36 months preceding the diagnosis of cancer. 8Y10 In a population-based study, we found that subjects with new-onset DM had an 8-fold higher risk of being diagnosed with PaC within 3 years of meeting criteria for DM, compared to the general population. 11 Based on these findings, new-onset DM in PaC has been postulated to be a paraneoplastic phenomenon caused by the cancer itself. 10, 12 However, whether this phenomenon is specific to PaC or to cancer in general has not been studied.
The aim of the present study was to retrospectively compare the prevalence and temporal correlation of DM in patients with the 4 most common cancers in the United States (lung, breast, prostate, and colorectal cancers) and noncancer controls to patients with PaC.
MATERIALS AND METHODS
This study was approved by the Mayo Foundation Institutional Review Board.
Patient Selection
From our database of patients, we identified consecutive patients who had diagnoses of lung cancer, breast cancer, prostate cancer, and colorectal cancer, at the Mayo Clinic, Rochester in 2007. Cases were age-and sex-matched to the first 100 consecutive patients with PaC seen at Mayo Clinic, Rochester in 2007. Sex matching was not performed for sexspecific cancers, that is, breast and prostate cancers. Controls were identified from patients followed at the Mayo Clinic's primary care clinics who had at least one physician visit in 2007. For noncancer controls with multiple visits in 2007, the clinic visit closest to July 1, 2007, was used as the index date.
Data Collection
The medical records of these 600 patients were reviewed to abstract demographic information and clinical data, including age, sex, family history of DM (grandparents, parents, siblings, and children), height, serial weights, serial blood glucose, DM status, duration of DM, and onset and date of cancer diagnosis. Height and weight were used to calculate body mass index (BMI, calculated by weight [kg]/height 2 [m 2 ]) at the index date. Note was also made for the proportion of patients in each group who did not have a fasting blood glucose (FBG) measurement before the index date.
Definitions
Subjects were defined as having DM using the 1997 American Diabetes Association (ADA) criteria (ie, an FBG Q126 mg/dL, random blood glucose [RBG] Q200 mg/dL, or hemoglobin A1c Q6.5%). 13 In keeping with the ADA guidelines, a repeat test was necessary to confirm the diagnosis of DM unless 2 different tests (FBG, RBG, or A1c) were concordant for the diagnosis of DM. 13 Patients who were on antidiabetic medications were classified as having DM as well. Onset of DM was defined by the date of the first of 2 consecutive tests that met the ADA criteria for DM diagnosis.
Duration of DM was defined as the time period between the onset of DM and the diagnosis of cancer. For noncancer controls, duration of DM was defined as the time period between the onset of DM and the index date. Diabetes mellitus was considered to be new onset if the onset preceded the cancer diagnosis by 36 months or less.
Statistical Analysis
While calculating the proportion of patients with DM in each group, the number of patients without a previous FBG measurement was subtracted from the denominator. The duration of DM was also calculated.
All statistical analyses were carried out using the SAS JMP 8 statistical software (Cary, NC). Statistical comparison of continuous variables was performed using the analysis of variance and t tests. Comparison of categorical variables was done using the Pearson W 2 test. P G 0.05 was considered statistically significant.
RESULTS

Patients' Demographics
The cohort of 600 patients had 100 patients each with lung cancer (mean age T SD, 71.6 T 9.4 years; 59 men), breast cancer (mean age T SD, 71.6 T 9.6 years), prostate cancer (mean age T SD, 71.3 T 9.4 years), colorectal cancer (mean age T SD, 71.6 T 9.5 years; 56 men), controls (mean age T SD, 70.7 T 9.2 years; 57 men), and PaC (mean age T SD, 71.6 T 9.4 years; 53 men) with no differences in the age distribution (P = 0.97) ( Table 1) . When sex predominant malignancies (breast and prostate cancer) were excluded, the sex distribution among the remaining groups was also similar (P = 0.86). A family history of DM was noted in 33% to 37% of patients in each of the 5 groups (P = 0.84). The mean BMI was comparable (P = 0.40) among breast cancer (mean T SD, 28.8 T 5.6 kg/m 2 ), prostate cancer (mean T SD, 28.6 T 3.8 kg/m 2 ), colorectal cancer (mean T SD, 28.4 T 6.1 kg/m 2 ), controls (mean T SD, 28.5 T 5.6 kg/m 2 ), and patients with PaC (mean T SD, 27.3 T 6 kg/m 2 ). The patients with lung cancer had a lower BMI (mean T SD, 26.8 T 4.7 kg/m 2 ) compared to those with breast cancer, colorectal cancer, prostate cancer, and the controls (P G 0.05) but were comparable to the patients with PaC (P = 0.60).
Blood Glucose Values
The mean T SD FBG in patients without DM was significantly higher in the patients with PaC (109.3 T 10.6 mg/dL) compared to those with colorectal cancer (103.1 T 10.2 mg/dL; P = 0.003), prostate cancer (102.6 T 9 mg/dL; P = 0.001), lung cancer (102 T 10.3 mg/dL; P = 0.0006), controls (100.3 T 9.2 mg/dL; P G 0.0001), and breast cancer (99.7 T 10 mg/dL; P G 0.0001). When the patients without PaC and the controls were compared, there was no difference in the FBG across the different groups, with the exception of the patients with breast cancer (99.7 T 10 mg/dL) who had a lower mean FBG compared to those with colorectal cancer (103.1 T 10.2 mg/dL) (P = 0.04).
Of the 600 patients, there were 35 patients (8 patients with lung cancer, 2 patients with breast cancer, 2 patients with colorectal cancer, 12 patients with prostate cancer, and 3 patients with pancreatic cancer) for whom a previous FBG measurement was not available. Whereas these patients did not carry a diagnosis of DM in their medical record and were not on antidiabetic medications, accurate glycemic status could not be ascertained in the absence of a previous blood glucose measurement. Therefore, these patients were not used in calculating the prevalence of DM. (Fig. 1 ). There was no difference in the prevalence of DM among the patients without PaC and the controls (P = 0.49).
Duration of Diabetes Mellitus
Data on duration of DM was available in 136 (59/66 patients with PaC, 14/18 patients with lung cancer, 17/19 patients with breast cancer, 7/13 patients with prostate cancer, 16/19 patients with colorectal cancer, and 23/23 controls) of the 158 patients who met the criteria for DM. The median duration of DM was 6 months (range, 0Y276 months) in the patients with PaC followed by 26 months (range, 3Y91 months) in those with prostate cancer, 52.5 months (range, 7Y249 months) in those with lung cancer, 120 months (range, 0Y230 months) in those with breast cancer, 110 months (range, 0Y324 months) in those with colorectal cancer, and 117 months (range, 0Y569 months) in the controls.
In the patients with PaC and DM, 59% (39/) of 66 patients developed DM in the 36 months preceding the diagnosis of PaC. In contrast, when patients with DM in the non-PaC group were compared, only 16% (3) of 18 patients with lung cancer, 21% (4) of 19 patients with breast cancer, 38% (5) of 13 patients with prostate cancer, 16% (3) of 19 patients with colorectal cancer, and 17% (4) of 23 patients controls developed DM in the 36 months preceding the diagnosis of cancer/index date. The prevalence of new-onset DM (developing in the 36 months preceding the diagnosis of cancer/index date) was markedly higher (P G 0.0001) in patients with PaC (40.2%) compared to those with lung cancer (3.3%), breast cancer (4.1%), prostate cancer (5.7%), colorectal cancer (3.3%), and controls (4.1%) (Fig. 2) .
DISCUSSION
In this retrospective study of 600 patients, we show that the prevalence of DM in PaC is high (68%) compared to that found in lung cancer, breast cancer, prostate cancer, colorectal cancer, prostate cancer, and noncancer control patients (14.8%Y23.5%).
This high prevalence of DM in PaC could not be explained based on classical risk factors for DM including age, sex, family history of DM or BMI, which were similar between the patients with PaC and the other groups. Even among the patients who did not meet the criteria for DM, the patients with PaC had a significantly higher mean FBG value (109.3 mg/dL) compared to other cancers and noncancer control patients (99.7Y103.1 mg/dL). Furthermore, most (59%) of DM in the patients with PaC was new onset (G36 months in duration) compared to only a minority (16Y38%) in the patients with other cancers and the noncancer controls.
Diabetes mellitus is a complex disorder that is characterized by hyperglycemia and is typically a result of an imbalance between insulin resistance and A-cell function. 14, 15 Type 2 DM commonly occurs as a result of increasing insulin resistance, typically in the context of weight gain, with a failure of the A cells to maintain a compensatory increase in insulin secretion. 15 In addition to the more commonly described type 2 DM, the ADA classifies DM into another subtype that is associated with diseases of the pancreas, processes that diffusely injure the pancreas resulting in development of DM. 16 As would be expected, the insult to the pancreas needs to be extensive before patients burn their endocrine pancreatic reserves and develop DM. 16 Whereas this is true of most pathophysiologic entities (eg, chronic pancreatitis) that result in the development of this type of DM, patients with PaC often develop DM at a time when the cancer might be small enough (typically in the 36 months preceding cancer diagnosis) to not be visualized on routine imaging, suggesting a different mechanism in the development of DM in this subgroup of patients. 17 This, together with the temporal correlation of the DM with the PaC (development in the 36 months preceding the cancer diagnosis) and resolution of the DM after cancer resection, has led to the proposal that DM in PaC is a paraneoplastic phenomenon. 10, 12, 18, 19 Our results lend further credence to the hypothesis that newonset DM is indeed unique to PaC and is relatively uncommon in other patients with cancers and those without cancer, suggesting that it is not merely a reflection of an increased risk of PaC in patients with DM but rather an early manifestation of the cancer. Furthermore, the finding that this high prevalence in PaC was noted despite no difference in canonical risk factors for DM including age, sex, family history, and BMI supports an alternative pathophysiologic basis for this type of DM. Previous studies have postulated the presence of a tumor-secreted factor that might mediate DM by inducing insulin resistance and/or causing A-cell function. 20Y22 This is reiterated by our observation that even patients without DM with PaC had higher mean FBG levels as compared to their non-PaC counterparts, suggesting significant alterations in glucose metabolism in patients with PaC.
New-onset DM in PaC is likely a paraneoplastic phenomenon mediated by tumor-secreted product(s). Because DM has a high prevalence in patients with PaC and develops at a time when the cancer may not even be visualized on imaging, patients with new-onset DM offer a group of high-risk patients who could be screened for sporadic pancreatic cancer. Further studies to discover the mediators of PaC-associated DM will not only improve our understanding of the pathophysiology of this phenomenon but could also offer potential biomarkers to screen patients for PaC.
